Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback